Today: 30 April 2026
Browse Category

NYSE:BIRK 24 September 2025 - 18 December 2025

Birkenstock (BIRK) Stock Slides on FY2026 Outlook as Tariffs and FX Bite, Despite a FY2025 Beat

Birkenstock (BIRK) Stock Slides on FY2026 Outlook as Tariffs and FX Bite, Despite a FY2025 Beat

Birkenstock shares fell 8% to $42.58 on Dec. 18 after the company posted record fiscal 2025 revenue of €2.1 billion and strong profit growth but issued cautious 2026 guidance citing tariff and currency pressures. The stock swung between $39.73 and $46.75 in heavy trading as investors reacted to margin concerns despite robust recent results.
18 December 2025
··
Birkenstock’s Big Footprint in 2025: Iconic Sandal Maker Defies Tariffs and Eyes Growth Surge

Birkenstock’s Big Footprint in 2025: Iconic Sandal Maker Defies Tariffs and Eyes Growth Surge

Birkenstock (NYSE: BIRK) traded near $46 on September 24, 2025, flat to its IPO price after a volatile two years. Q3 FY2025 revenue rose 12% year-over-year to €635 million, with double-digit growth across all regions. Majority owner L Catterton holds about 73% of shares after a secondary sale in 2024. Shares are down 14% year-to-date and 8.5% over three months.
24 September 2025
·

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop